盐酸氯胺酮(Ketamine Hydrochloride) - 药物靶点：NMDA receptor_在研适应症：疼痛，麻醉，自杀意念_专利_临床

概要

基本信息

简介小分子药物氯胺酮作为 N-甲基-D-天冬氨酸 (NMDA) 受体的调节剂，以商品名 KETALAR 销售，主要用作麻醉药。 1970 年，Endo International 首次在美国批准氯胺酮用于医疗用途。该药物可作为微酸性无菌溶液用于静脉内或肌肉内注射，每毫升多剂量小瓶含有 10 毫克氯胺酮碱。氯胺酮起效迅速并产生镇静、解离和镇痛作用。它通常用于手术过程中的麻醉，并作为慢性疼痛患者的止痛药。氯胺酮作为抗抑郁药可能具有一定的潜力，但需要更多的研究来确定其对该适应症的疗效和安全性。使用氯胺酮作为麻醉剂或止痛药可能会引起一些副作用，包括幻觉、恶心和呕吐。

药物类型

小分子化药

别名

(+-)-Ketamine、(±)-ketamine、2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone

+ [41]

靶点

NMDA receptor

作用方式

调节剂

作用机制

NMDA receptor调节剂(谷氨酸[NMDA]受体复合体调节剂)

治疗领域

神经系统疾病其他疾病遗传病与畸形+ [6]

在研适应症

疼痛麻醉自杀意念+ [19]

非在研适应症

肌萎缩侧索硬化自闭症谱系障碍拇囊炎+ [4]

原研机构

Endo International Plc

在研机构

Neurocentrx Pharma Ltd.HolsboerMaschmeyer NeuroChemie (Germany)

iX Biopharma Ltd.

+ [18]

非在研机构

Novartis Pharma AG

Roivant Sciences, Inc.

Novartis AG

+ [2]

权益机构

Seelos Therapeutics, Inc.

Nephron Pharmaceuticals LLC

Kymanox Corp.

+ [13]

最高研发阶段批准上市

首次获批日期

美国 (1970-02-19),

麻醉

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、孤儿药 (美国)、创新许可和获取途径 (英国)、局长国家优先审评券 (美国)

登录后查看时间轴

结构/序列

分子式C13H17Cl2NO

InChIKeyVCMGMSHEPQENPE-UHFFFAOYSA-N

CAS号1867-66-9

关联

2,271

项与盐酸氯胺酮相关的临床试验

IRCT20161022030421N3

/ Suspended临床3期IIT

Comparison of the effect of intravenous ketamine and midazolam as a premedication in children undergoing cochlear implantation at the time of separation from parents

开始日期2640-01-21

申办/合作机构

Baqiyattallah University of Medical Sciences

NCT05945147

/ Withdrawn临床2期IIT

Feasibility Study Comparing a Ketamine and Midazolam Infusion to a Midazolam-Only Infusion for Complex Regional Pain Syndrome

This study will assess the feasibility of administering ketamine plus midazolam or midazolam alone, when infused over 5 days in an outpatient setting, to adults with complex regional pain syndrome (CRPS).

开始日期2099-01-01

申办/合作机构

Stanford University

NCT06816433

/ Suspended临床2期IIT

A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members, Veterans, and Non-Veteran Civilians With PTSD

This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for Post Traumatic Stress Disorder (PTSD) utilizing an adaptive platform trial (APT) design.
Intervention D - SLS-002 will assess the safety and efficacy of SLS-002 in participants with PTSD.
Please see NCT05422612 for information on the S-21-02 Master Protocol.

开始日期2028-05-01

申办/合作机构

Cambridge Cognition Ltd.

[+5]

100 项与盐酸氯胺酮相关的临床结果

登录后查看更多信息

100 项与盐酸氯胺酮相关的转化医学

登录后查看更多信息

100 项与盐酸氯胺酮相关的专利（医药）

登录后查看更多信息

27,950

项与盐酸氯胺酮相关的文献（医药）

2026-12-31·Canadian Journal of Pain-Revue Canadienne de la Douleur

PAINscape—Exploring patient experiences with ketamine for chronic neuropathic pain: A qualitative study

Article

作者: Lu, Mindy ; Mattina, Gabriella ; Parakh, Nandana ; Goel, Akash ; Ladha, Karim S ; Tucci, Victoria ; Hanlon, John G ; Ritvo, Paul ; Pritlove, Cheryl ; Leda, Mariela ; Clarke, Hance ; Dang, Kevin ; Rizvi, Sakina J ; Pazmino-Canizares, Janneth ; Thomas, Zaaria ; Wijeysundera, Duminda N ; Lessor, Danielle ; Pereira, Sérgio M ; Nayar, Roshni

Background/Aims:

Chronic pain affects approximately 8 million Canadians annually and is defined by persistent pain lasting over 3 months. Ketamine is an anesthetic drug used to treat chronic neuropathic pain, a subset of chronic pain. To better understand ketamine's therapeutic benefits and feasibility as a treatment for chronic neuropathic pain, it is important to characterize patient experiences and perspectives with ketamine, as well as barriers and facilitators to accessing this treatment.

Methods:

Thirteen participants were recruited from the chronic pain ketamine infusion program at St. Michael's Hospital in Toronto, Canada. Each participant completed a survey that captured demographic information and chronic pain features, followed by a semistructured interview. Interview data were analyzed, and themes were generated using content analysis.

Results:

All participants described decreased pain intensity and increased functionality after receiving ketamine treatment. Barriers to ketamine treatment included fragmented health systems and long wait times, along with a struggle for pain validation by health care providers. Facilitators of ketamine treatment included support from individual health care providers and the provision of a supportive treatment environment.

Conclusions:

Although pain experiences differed among participants, all participants reported decreased pain with ketamine infusions. Addressing the stigma associated with ketamine infusions, further research around augmenting durability of ketamine, and providing a safe treatment environment can all improve ketamine's benefit for chronic neuropathic pain. Understanding the barriers and facilitators, as well as implementing participant suggestions, will not only help inform our ketamine program but can improve access to pain management and facilitate future research in this field.

2026-12-01·MOLECULAR BIOLOGY REPORTS

Ketamine enantiomers and the gut microbiota: mechanisms, clinical implications, and future directions

Review

作者: Zhou, Li-Wen ; Xie, Jin-Xi

2026-12-01·Current Pain and Headache Reports

Neuroscientific Basis of Ketamine as an Analgesic and Emerging Role in the Management of Depression

Review

作者: Kaye, Alan D ; Shekoohi, Sahar ; Meyer, Tricia A ; Coggins, Navy C ; Patel, Mihir ; Chokr, Hanson A

1,230

项与盐酸氯胺酮相关的新闻（医药）

2026-06-19

·solvonis.com

Solvonis Announces Result of Annual General Meeting

LONDON – June 19, 2026 – Solvonis Therapeutics plc (LSE: SVNS) (“Solvonis” or the “Company”), a late clinical stage biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces that at the Annual General Meeting of the Company held earlier today, all resolutions put to shareholders were duly passed. Voting on all resolutions was conducted by way of a poll. Full details of the poll results are set out below. Dennis Purcell, Non-Executive Chairman of Solvonis, commented: “On behalf of the Board, I would like to thank shareholders for their continued support at today’s Annual General Meeting. “The past year has been an important period in the development of Solvonis, during which the Company completed its transition into a focused CNS therapeutics business and established a broader, more coherent portfolio across addiction and psychiatry. “We are pleased with the balanced progress being made across the portfolio, including our later-stage clinical programmes in Alcohol Use Disorder and our emerging discovery and preclinical opportunities in PTSD, stimulant use disorder and depression. “The Board remains focused on disciplined execution, capital-efficient development and creating long-term value for shareholders. We look forward to updating the market, as appropriate, on continued progress across the portfolio through the remainder of 2026.” The Company’s strategy is to build a differentiated CNS therapeutics portfolio across areas of high unmet need, with later-stage clinical assets complemented by internally generated discovery programmes. Solvonis’ current portfolio includes SVN-001, its lead programme in severe Alcohol Use Disorder; SVN-002, its U.S.-focused Alcohol Use Disorder programme; and discovery and preclinical programmes including SVN-114 in PTSD and SVN-015 in stimulant use disorder and depression. Voting Results: Resolution Votes for % Votes Cast Votes against % Votes Cast Total Votes Votes withheld Resolution 1 (Ordinary)To receive the report and accounts for the year ended 31 December 2025 1,155,565,533 96.16% 46,093,340 3.84% 1,201,658,873 1,589,104 Resolution 2 (Ordinary)To approve the remuneration policy 1,113,689,240 95.46% 52,967,133 4.54% 1,166,656,373 36,591,604 Resolution 3 (Ordinary)To approve the remuneration report 1,113,689,240 95.46% 52,967,133 4.54% 1,166,656,373 36,591,604 Resolution 4 (Ordinary)To re-appoint Kreston Reeves LLP as auditor 1,197,595,249 99.53% 5,652,728 0.47% 1,203,247,977 0 Resolution 5 (Ordinary)To re-appoint Paul Carter as a director 1,151,080,001 95.66% 52,167,976 4.34% 1,203,247,977 0 Resolution 6 (Ordinary)To re-appoint Anthony Tennyson as a director 1,151,313,351 99.49% 5,934,626 0.51% 1,157,247,977 46,000,000 Resolution 7 (Ordinary)To re-appoint Nicholas Nelson as a director 1,151,080,001 95.66% 52,167,976 4.34% 1,203,247,977 0 Resolution 8 (Ordinary)To authorise the directors to allot equity 1,146,194,662 95.26% 57,053,315 4.74% 1,203,247,977 0 Resolution 9 (Special)That a general meeting, other than an AGM, may be called on not less than 14 days’ notice 1,162,592,749 96.62% 40,655,228 3.38% 1,203,247,977 0 Resolution 10 (Special) To disapply pre-emption rights 1,026,314,705 94.85% 55,700,737 5.15% 1,082,015,442 121,232,535 Resolution Votes for % Votes Cast Votes against % Votes Cast Total Votes Votes withheld Resolution 1 (Ordinary) To receive the report and accounts for the year ended 31 December 2025 1,155,565,533 96.16% 46,093,340 3.84% 1,201,658,873 1,589,104 Resolution 2 (Ordinary) To approve the remuneration policy 1,113,689,240 95.46% 52,967,133 4.54% 1,166,656,373 36,591,604 Resolution 3 (Ordinary) To approve the remuneration report 1,113,689,240 95.46% 52,967,133 4.54% 1,166,656,373 36,591,604 Resolution 4 (Ordinary) To re-appoint Kreston Reeves LLP as auditor 1,197,595,249 99.53% 5,652,728 0.47% 1,203,247,977 0 Resolution 5 (Ordinary) To re-appoint Paul Carter as a director 1,151,080,001 95.66% 52,167,976 4.34% 1,203,247,977 0 Resolution 6 (Ordinary) To re-appoint Anthony Tennyson as a director 1,151,313,351 99.49% 5,934,626 0.51% 1,157,247,977 46,000,000 Resolution 7 (Ordinary) To re-appoint Nicholas Nelson as a director 1,151,080,001 95.66% 52,167,976 4.34% 1,203,247,977 0 Resolution 8 (Ordinary) To authorise the directors to allot equity 1,146,194,662 95.26% 57,053,315 4.74% 1,203,247,977 0 Resolution 9 (Special) That a general meeting, other than an AGM, may be called on not less than 14 days’ notice 1,162,592,749 96.62% 40,655,228 3.38% 1,203,247,977 0 Resolution 10 (Special) To disapply pre-emption rights 1,026,314,705 94.85% 55,700,737 5.15% 1,082,015,442 121,232,535 As at 19 June 2026, there were 6,806,403,493 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and have not been included in the calculation of the proportion of votes for or against a resolution. The full text of each resolution is available in the Notice of Annual General Meeting, published on the Company's website. Enquiries: Solvonis Therapeutics plcAnthony Tennyson, CEO & Executive Directorinfo@solvonis.comSinger Capital Markets (Broker)Russell Cook+44 (0) 20 7496 3000 About Solvonis Therapeutics plc Solvonis Therapeutics plc (LSE: SVNS) is a late clinical-stage biopharmaceutical company developing small-molecule therapeutics for high-burden central nervous system (“CNS”) disorders. Headquartered in London and listed on the Main Market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline across addiction and psychiatry, combining later-stage clinical programmes with proprietary discovery-stage assets. The Company’s lead clinical programme, SVN-001, is currently in Phase 3 for severe Alcohol Use Disorder (“AUD”) in the UK, while SVN-002 is being advanced towards a planned Phase 2b trial in the United States targeting moderate-to-severe AUD. Solvonis is also advancing proprietary discovery and preclinical programmes across Post-Traumatic Stress Disorder (“PTSD”), stimulant use disorder and depressive disorders. These include SVN-114, a lead candidate from the Company’s PTSD discovery programme, and SVN-015, a novel serotonin-dopamine reuptake inhibitor being evaluated for stimulant use disorder, with additional depression-related optionality. In parallel, Solvonis is continuing to build its proprietary CNS discovery platform, supported by a dedicated compound library, to identify and develop new small-molecule modulators of key neurotransmitter systems relevant to addiction and psychiatry.

临床2期临床3期高管变更

2026-06-18

·GlobeNewswire-Health Care

Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC informing the Company that, as of June 17, 2026, it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). Silo’s common stock continues to trade on the Nasdaq Capital Market, and the matter is now closed. “We appreciate the loyalty and continuing support from our investors for our business strategies aimed at creating long-term value for stockholders. Looking ahead, we remain confident about our progress toward a first-in-human clinical trial of our lead drug SPC-15 targeting PTSD and successfully advancing our AI agents platform QwikAgents,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. About Silo Pharma, Inc.Silo Pharma is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com Forward Looking StatementsThis news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law. Contact(800) 705-0120investors@silopharma.com

2026-06-18

·BioSpace

HMNC Brain Health announces $50 million first closing of Series B financing and a strategic partnership with MEDICE

Financing will accelerate the development of HMNC’s neurosciences portfolio, including Phase 3-readiness activities for Ketabon (KET01) and Nelivabon (BH-200) Agreement grants MEDICE exclusive European commercialization rights for KET01, with tiered double-digit royalties and significant milestone payments MUNICH, Germany, June 15, 2026 – HMNC Brain Health ("HMNC" or the "Company"), a clinical-stage neuroscience company, today announced the successful $50 million first closing of its Series B financing to support the advancement of the Company’s Ketabon (KET01) and Nelivabon (BH-200) clinical programs. MEDICE – The Health Family (“MEDICE”) led the financing round as the main investor. MEDICE is one of the leading healthcare companies with a focus on mental health and is a market leader in the ADHD segment in several European countries. In addition, existing investor The Maschmeyer Group also participated in this round. Proceeds will support the late-stage clinical development of HMNC’s neuroscience portfolio, including Phase 3-readiness activities for Ketabon (KET01) and Nelivabon (BH-200). Ketabon (KET01) is an oral prolonged-release ketamine formulation for treatment-resistant depression (TRD), developed as a differentiated and scalable treatment option for outpatient and at-home use. Phase 2 studies have demonstrated rapid antidepressant effects and reduced dissociative side effects compared with existing ketamine-based therapies. Nelivabon (BH-200) is a first-in-class oral vasopressin V1b receptor antagonist being developed as a biomarker-guided precision therapy for biologically defined depressive disorders. The program has generated encouraging Phase 2b results in the OLIVE study and is supported by a proprietary genetic patient stratification approach. HMNC is also evaluating the potential expansion of the program into additional neuroscience indications. In parallel, MEDICE has entered into a strategic licensing agreement for the European commercialization of KET01. Under the terms of the agreement, HMNC and its affiliates are eligible to receive tiered double-digit royalties on net sales and significant success-based commercial milestone payments. The partnership combines HMNC’s differentiated neuroscience pipeline and precision capabilities with MEDICE’s established European commercial infrastructure in the field of mental health. Dr. Maximilian Doebler, Managing Director & Chief Business Officer, HMNC , said: “Securing this financing alongside a strategic partner like MEDICE validates our scientific approach and our broader vision of building a next-generation neuroscience company. MEDICE brings the expertise and commercial infrastructure to help bring KET01 to patients at scale, and we are excited to partner with such an experienced and highly regarded team.” Dr. Dr. Jessica Burgstaller, VP Strategy & Corporate Development, HMNC , said: “This partnership is an important step toward bringing our scientific insights closer to patients. Seeing years of research translate into meaningful new treatment options for patients further strengthens our conviction that precision neuroscience can reshape mental health treatment. At the same time, we are committed to improving access to safe and rapid-acting ketamine-based therapies.” “Mental health is at the heart of what MEDICE does, and Ketabon represents a compelling opportunity to expand our presence in depression treatment with a differentiated approach. We are also excited by the potential of HMNC’s biomarker-guided precision portfolio, including Nelivabon, which reflects where we believe the field is heading. By combining MEDICE’s commercial infrastructure and neuropsychiatry expertise with HMNC’s innovation capabilities, we are well positioned to help bring these programs to patients across Europe,” said Dr. med. Katja Pütter-Ammer, Managing Partner of MEDICE. KET01 and BH-200 are investigational therapies and are not approved by regulatory authorities. -END- Contact HMNC Brain Health Dr. Maximilian Doebler, Managing Director & Chief Business Officer E-mail: maximilian.doebler@hmnc-brainhealth.com Dr. Dr. Jessica Burgstaller, VP Strategy & Corporate Development E-mail: jessica.burgstaller@hmnc-brainhealth.com MEDICE – The Health Family Harald Goeßl, Head of Corporate Communications E-mail: H.Goessl@medice.de ICR Healthcare Tracy Cheung / Ashley Tapp / Kris Lam E-mail: HMNCBrainHealth@icrhealthcare.com About HMNC Brain Health (HMNC Holding GmbH) HMNC Brain Health (HMNC) is a clinical-stage neuroscience company pioneering new therapies for mental health disorders. Its pipeline includes Nelivabon (BH-200), a vasopressin V1b receptor antagonist being developed as a biomarker-guided precision therapy for biologically defined depressive disorders. Used with a genetic test to identify patients most likely to benefit, Nelivabon offers a precision neuroscience approach to treatment. HMNC is also developing Ketabon (KET01), an oral prolonged-release ketamine formulation for treatment-resistant depression, designed as a differentiated and scalable option for outpatient and at-home use. By advancing targeted and accessible treatment options, HMNC aims to address significant unmet needs of millions of patients who are not helped sufficiently by existing mental health therapies. The Company is headquartered in Munich, Germany. Find out more at and connect with us on LinkedIn . About the Ketabon Program Ketabon is a joint venture between HMNC Brain Health and Develco Pharma focused on developing KET01, an oral prolonged-release ketamine formulation for treatment-resistant depression (TRD). Designed for safe and convenient at-home treatment, KET01 has demonstrated rapid antidepressant effects with minimal dissociative side effects in Phase 2 studies, potentially offering an important differentiated alternative to existing ketamine-based therapies. About MEDICE – The Health Family MEDICE – The Health Family is a third-generation, family-run pharmaceutical company, operating for over 75 years, that focuses on providing integrated, multimodal healthcare solutions. The company develops high-quality prescription (RX) and self-medication (PCC) products, alongside digital health and nutritional concepts. View the full company pro Welcome to the MEDICE Health Family .

100 项与盐酸氯胺酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00711	盐酸氯胺酮	N01AX03	DBSALT000396

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
疼痛	美国	Pharmather Holdings Ltd.	2025-08-08
麻醉	美国	Ph Healthcare Services	1970-02-19

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
自杀意念	申请上市	美国	Pharmather Holdings Ltd.	2025-03-11
双相情感障碍及相关疾病	临床3期	美国	NeuroRx, Inc.	2022-01-30
躁郁症	临床3期	美国	NeuroRx, Inc.	2019-06-25
酒精使用障碍	临床3期	英国	Solvonis Therapeutics Plc	-
创伤后应激障碍	临床2期	美国	Seelos Therapeutics, Inc.	2023-11-27
Rett综合征	临床2期	美国	Pharmather Holdings Ltd.	2023-02-02
药物性运动障碍	临床2期	美国	Pharmather, Inc.	2021-10-05
帕金森病	临床2期	美国	Pharmather, Inc.	2021-10-05
丛集性头痛	临床2期	丹麦	Cch Pharma Pty Ltd.	2019-11-20
重度抑郁症	临床2期	澳大利亚	Douglas Pharmaceuticals Ltd.	2019-05-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04955470 (Pubmed \| CJEM)	临床2期	自杀意念	15	Intravenous ketamine (0.5 mg/kg)	選簾遞遞鑰餘鏇範鑰艱(餘鏇餘壓鹽構願願蓋艱) = No serious or unexpected adverse events occurred. 獵廠選顧遞遞糧艱繭艱 (艱鬱憲鑰簾淵憲憲餘蓋 )	积极	2026-06-03
				Midazolam (0.03 mg/kg)
NCT01969227 (CTgov)	N/A	气道阻塞	15	Propofol+Ketamine	襯夢壓製選鬱夢膚築願(鹹繭繭鏇膚築窪繭鹽衊) = 範繭醖鹹製憲憲顧膚鹹鑰窪襯鹽鹽網鹹衊壓選 (艱構鏇壓窪窪淵簾廠簾, 夢鹹艱鏇襯窪醖膚構遞 ~ 鬱鏇製憲齋製觸艱遞鏇) 更多	-	2026-05-19
NCT03470675 (CTgov)	临床4期	产后抑郁症 \| 会阴痛	67	Epidural saline + IV saline (Epidural Saline + IV Saline)	觸蓋鹽遞憲範淵鹹壓壓(夢淵獵製選鹹鹽鹽網鹽) = 廠鬱鬱廠選獵網鹽製鑰遞醖鹽壓鑰觸齋窪餘淵 (積齋糧簾獵夢夢糧觸鑰, 繭構艱網鑰製顧繭網齋 ~ 鬱廠艱網顧壓齋壓糧築) 更多	-	2026-04-24
				Epidural morphine 3 mg + IV saline (Epidural Morphine 3 mg + IV Saline)	觸蓋鹽遞憲範淵鹹壓壓(夢淵獵製選鹹鹽鹽網鹽) = 願鹹壓壓餘蓋齋網選蓋遞醖鹽壓鑰觸齋窪餘淵 (積齋糧簾獵夢夢糧觸鑰, 齋構艱淵餘糧醖餘廠網 ~ 鬱製觸艱夢糧窪艱壓鬱) 更多
NCT06317636 (Pubmed \| Pain Manag)	临床2期	抑郁症 \| 慢性疼痛	42	Ketamine	壓製範鏇顧襯鏇觸窪構(艱範壓膚鏇鏇築構憲觸) = 築餘鹹蓋壓糧願醖願鑰糧糧獵夢鬱鏇餘淵窪糧 (餘窪製觸獵鑰獵鏇壓廠 ) 更多	积极	2026-04-16
NCT05518877 (CTgov)	临床4期	镇痛 \| 急性疼痛	55	Ketamine (Ketamine 15 Minutes)	壓鏇襯餘顧壓衊襯醖構(鏇範醖製範鑰範構膚願) = 膚繭窪觸觸構壓夢襯壓壓鹹糧簾廠壓齋衊壓醖 (繭襯觸鬱壓膚築願觸積, 0.57) 更多	-	2026-04-13
				ketamine (Ketamine 30 Minutes)	壓鏇襯餘顧壓衊襯醖構(鏇範醖製範鑰範構膚願) = 齋鹽衊窪選衊選鏇鑰網壓鹹糧簾廠壓齋衊壓醖 (繭襯觸鬱壓膚築願觸積, 0.25) 更多
NCT06138691 (KET-RO, CTgov)	临床1期	难治性抑郁症	16	RO+Ketamine (Ketamine and RO DBT)	簾壓餘鏇網顧壓繭蓋艱(鬱遞衊顧範遞蓋簾衊齋) = 蓋選範構築憲窪鹽憲糧選製網壓構廠醖顧醖鬱 (襯繭鏇齋構鹽窪鹹廠艱, 8.69) 更多	-	2026-03-30
				RO+Ketamine (Within Ketamine Session and Ketamine + RO DBT)	獵選構蓋憲範製遞膚製(餘憲鬱蓋網鹹艱構糧餘) = 鑰製餘繭醖選網醖製構窪鑰艱選遞築鹽遞膚遞 (醖襯繭鏇壓鑰憲淵觸廠, 14.97) 更多
NCT05277896 (RSI, CTgov)	临床4期	呼吸衰竭	2,367	Ketamine (Ketamine Group)	齋蓋選繭積選選選鑰窪 = 築糧廠網獵構襯襯膚製憲艱餘齋繭範壓壓齋觸 (夢窪獵構廠衊糧選夢襯, 廠艱鑰築簾鏇膚積廠願 ~ 憲遞糧淵遞積構醖夢選) 更多	-	2026-03-25
				Etomidate (Etomidate Group)	齋蓋選繭積選選選鑰窪 = 窪鑰鹽築夢顧淵願餘醖憲艱餘齋繭範壓壓齋觸 (夢窪獵構廠衊糧選夢襯, 製齋構鬱鏇糧簾壓觸積 ~ 築憲窪夢艱齋蓋糧構觸) 更多
NCT07059429 (KETARTHRO, CTgov)	N/A	阿片滥用 \| 镇痛 \| 术后疼痛	100	ketamine (Ketamine Plus Standard Analgesia)	憲選壓繭願鏇獵獵觸繭(糧繭選繭襯窪鑰衊艱糧) = 願淵襯鏇築鏇鬱築夢鹹憲醖鬱網淵淵製窪鏇夢 (淵衊襯觸積構鹹積襯繭, 簾鹽鬱衊鏇構餘餘艱衊 ~ 鑰遞繭艱繭遞網鹹蓋齋) 更多	-	2026-03-02
				Standard Analgesia (Standard Analgesia Alone)	憲選壓繭願鏇獵獵觸繭(糧繭選繭襯窪鑰衊艱糧) = 衊鑰膚鹽鏇襯鹽鏇憲窪憲醖鬱網淵淵製窪鏇夢 (淵衊襯觸積構鹹積襯繭, 獵鏇餘網網選壓淵衊艱 ~ 艱壓積簾壓築築夢艱鏇) 更多
NCT07337135 (CTgov)	N/A	减肥手术并发症 \| 麻醉 \| 术后疼痛 ... 更多	60	Remifentanil (Opioid-Based Anesthesia (OBA))	餘鹽顧築糧網觸獵齋夢(繭遞觸糧獵襯顧積選築) = 構顧壓網鬱築憲艱鬱鏇繭淵鹹觸觸衊積醖鏇衊 (鹽遞襯築壓夢鹽鹽鏇廠, 膚廠願膚壓蓋鏇構繭選 ~ 蓋鹹簾網鬱鏇網齋獵遞) 更多	-	2026-02-25
				Dexmedetomidine+Lidocaine+Ketamine (Opioid-Free Anesthesia (OFA))	餘鹽顧築糧網觸獵齋夢(繭遞觸糧獵襯顧積選築) = 繭築鹹窪遞鑰範鑰糧選繭淵鹹觸觸衊積醖鏇衊 (鹽遞襯築壓夢鹽鹽鏇廠, 糧鹹廠鏇餘鹹網築衊顧 ~ 餘蓋窪廠獵醖淵繭襯觸) 更多
NCT05320107 \| NCT05320120 (Pubmed \| Ther Adv Psychopharmacol)	临床1期	-	67	S-ketamine	糧鑰積繭鏇壓窪餘簾蓋(餘鏇構簾糧網淵簾鹹顧) = late ketamine administration resulted in reduced calcarine gyrus activation in men compared to women, independent of sexual arousal (β ≤ −0.23, CI 95 ≤ (−0.52, 0.05)). This finding was confirmed for resting activity under subacute ketamine (β = −0.18, CI 95 = (−0.32, −0.04)) 獵餘壓鏇餘蓋繭鏇窪選 (觸襯壓鬱糧顧餘窪壓窪 ) 更多	不佳	2026-02-01
				Racemic ketamine